Baltimore, MD · Founded 2014 · Privately Held (backing)
Developer of in vitro diagnostic tests designed to aid diagnosis and screening for bacterial and fungal lung infections. Pearl Diagnostics is based in Baltimore, MD and was founded in 2014. Its last reported valuation was $15 million in Jun 2022. It has raised $4.5 million across 2 recorded rounds; the latest was an $11.2 million early-stage round in Mar 2026.
Last reported valuation
$15.0M
Oct 2026
Priced at
—
Total raised
$4.5M
Last round
Early Stage VC
Mar 2026
No prints on record
No secondary trades in Pearl Diagnostics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Pearl Diagnostics with a free account
·The complete investor list: 11 names
·Watch Pearl Diagnostics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Pearl Diagnostics stock.
